Posted by Surbhi on July 09 2026 at 06:02 PM
public
IL-23 inhibitors in IBD treatment — the selective biologics targeting the p19 subunit of interleukin-23 (risankizumab/Skyrizi, guselkumab/Tremfya, mirikizumab/Omvoh) demonstrating superior effica...
Posted by Adam aam on September 26 2026 at 01:44 PM
public
Rockville, MD., September 26, 2026 — The Targeted Oncology Biologics Market is projected to grow from USD 71.01 billion in 2026 to USD 162.04 billion by 2036, advancing at a 8.6% CAGR during the ...
Sports Medicine Biologics Market: Growth, Trends, Demand & Forecast to 2034
Sports Medicine Biologics Market Overview
The Sports Medicine Biologics Market is expanding as athletes, sports m...
Posted by Mayur on September 21 2026 at 02:11 PM
public
The global biologics contract manufacturing market is undergoing significant expansion as pharmaceutical and biotechnology companies increasingly outsource development and manufacturing activitie...
Posted by Mayur on September 18 2026 at 01:44 PM
public
The Asia Pacific biologics contract manufacturing market is entering a high-growth phase, supported by rising biopharmaceutical demand, expanding biologics pipelines, and increasing outsourcing a...
